Scarica l'app Stockscreener
6.77
3.15%
-0.22
Pre-mercato:
6.56
-0.21
-3.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SAGE Giù?
Forum
Previsione
Sage Therapeutics Inc Borsa (SAGE) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation - ACCESS Newswire
How To Trade (SAGE) - news.stocktradersdaily.com
Shareholders Filed a Lawsuit Against Sage Therapeutics for Failed Drug Launch - TradingView
INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. and Encourages Long-Term Investors to Contact the FirmSAGE - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc. (SAGE) Shareholders - ACCESS Newswire
Bank of America Corp DE Sells 355,277 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
ProShare Advisors LLC Boosts Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Ameriprise Financial Inc. Trims Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - ACCESS Newswire
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Trims Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Deutsche Bank AG Buys 20,504 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Wall Street Zen Upgrades Sage Therapeutics (NASDAQ:SAGE) to “Hold” - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Zurzuvae®: The Value Spills Over - Leerink Partners
Man Group plc Takes Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Purchased by Millennium Management LLC - Defense World
BNP Paribas Financial Markets Increases Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Northern Trust Corp Boosts Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect - Louisiana First News
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics - ACCESS Newswire
What's The Risk Of Letting Researchers Use LLMs? - Clinical Leader
Sage Therapeutics (NASDAQ:SAGE) Lowered to Sell Rating by StockNews.com - Defense World
Sage Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView
How the (SAGE) price action is used to our Advantage - news.stocktradersdaily.com
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Jane Street Group LLC Raises Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - ACCESS Newswire
Dimensional Fund Advisors LP Reduces Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Sage Therapeutics Brass Sued Over Drug Candidate Claims - Law360
Voya Investment Management LLC Raises Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lifshitz Law PLLC Announces Investigations of Extreme Networks, Inc. (NASDAQ:EXTR), Methode Electronics, Inc. (NYSE:MEI), Sage Therapeutics, Inc. (NASDAQ:SAGE), and New Fortress Energy, Inc. (NASDAQ:NFE) - Louisiana First News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Wells Fargo & Company MN Boosts Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Lost Money on Sage Therapeutics, Inc.(SAGE)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
Barclays PLC Decreases Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Where are the Opportunities in (SAGE) - news.stocktradersdaily.com
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial - The Globe and Mail
Sage Therapeutics (NASDAQ:SAGE) Upgraded at StockNews.com - Defense World
Invesco Ltd. Purchases 4,629 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Q2 Earnings Forecast for Sage Therapeutics Issued By Wedbush - Defense World
HC Wainwright Issues Positive Estimate for SAGE Earnings - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
What is HC Wainwright’s Forecast for SAGE Q1 Earnings? - Defense World
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - MSN
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2025 Earnings Call Transcript - Insider Monkey
Sage Therapeutics’ Earnings Call Highlights Growth and Uncertainty - TipRanks
Balance Sheet Breakdown: Sage Therapeutics Inc (SAGE)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ... - Yahoo Finance
SAGE Reports Q1 Revenue Below Estimates, Highlights ZURZUVAE Gro - GuruFocus
Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: S - GuruFocus
Sage Therapeutics Reports Strong Q1 2025 Performance - TipRanks
Sage Therapeutics outlines Q1 2025 growth in ZURZUVAE prescriptions and pipeline progress - MSN
Sage Therapeutics Q1 2025 Earnings: Revenue at $13.8M Misses Est - GuruFocus
Sage Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SAGE) - Seeking Alpha
Earnings call transcript: Sage Therapeutics misses Q1 2025 EPS forecast By Investing.com - Investing.com Nigeria
Earnings call transcript: Sage Therapeutics misses Q1 2025 EPS forecast - Investing.com Australia
0.92%
7.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):